Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
Chemoimmunotherapy with hyper-CVAD is an effective frontline regimen for ALL. Ofatumumab potently binds to CD20 with better in vitro activity than rituximab. We hypothesized that addition of ofatumumab (O) to hyper-CVAD may improve outcomes in CD20+ ALL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Abhishek Maiti, Hagop Kantarjian, Farhad Ravandi, Deborah Thomas, Maria Khouri, Guillermo Garcia-Manero, Rebecca Garris, Jorge Cortes, Nicholas Short, Koji Sasaki, Ghayas Issa, Paul Koller, Heather Schroeder, Tapan Kadia, Srdan Verstovsek, Naval Daver, Ni Source Type: research